(vianews) - ucb (ucb.br) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| ucb (ucb.br) | €108.20 | 1.3% | 3.8% |
| vetoquinol (veto.pa) | €97.10 | 1.02% | 12.13% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. ucb (ucb.br)
1.3% forward dividend yield and 3.8% return on equity
ucb sa, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. the company's primary products include cimzia for inflammatory tnf mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; vimpat, keppra, and briviact for epilepsy; neupro for parkinson's disease and restless legs syndrome; nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and zyrtec and xyzal for allergies. it also offers evenity for the treatment of osteoporosis in postmenopausal women; bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and fintepla to treat dravet syndrome. in addition, the company is involved in developing rozanolixizumab and zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat cdkl5 deficiency disorder; doxecitine for tk2 deficiency disorder; staccato alprazolam for stereotypical prolonged seizures; bepranemab to treat alzheimer's disease; minzasolmin and ucb0222 for parkinson's disease; and ucb1381 and ucb9741 for atropic dermatitis. further, it engages in contract manufacturing activities. ucb sa has collaboration agreements with amgen, biogen, roche/genentech, novartis, and otsuka. the company was incorporated in 1925 and is headquartered in brussels, belgium.
earnings per share
as for profitability, ucb has a trailing twelve months eps of €1.77.
pe ratio
ucb has a trailing twelve months price to earnings ratio of 61.13. meaning, the purchaser of the share is investing €61.13 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.8%.
volatility
ucb's last week, last month's, and last quarter's current intraday variation average was 0.44%, 0.75%, and 1.20%.
ucb's highest amplitude of average volatility was 2.04% (last week), 1.46% (last month), and 1.20% (last quarter).
moving average
ucb's value is way above its 50-day moving average of €93.50 and way higher than its 200-day moving average of €81.75.volume
today's last reported volume for ucb is 28152 which is 90.55% below its average volume of 297959.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ucb's stock is considered to be oversold (<=20).
more news about ucb.
2. vetoquinol (veto.pa)
1.02% forward dividend yield and 12.13% return on equity
vetoquinol sa, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in europe, the americas, and the asia pacific region. it provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. the company was founded in 1933 and is headquartered in lure, france. vetoquinol sa is a subsidiary of soparfin sca.
earnings per share
as for profitability, vetoquinol has a trailing twelve months eps of €4.97.
pe ratio
vetoquinol has a trailing twelve months price to earnings ratio of 19.54. meaning, the purchaser of the share is investing €19.54 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.13%.
revenue growth
year-on-year quarterly revenue growth declined by 5.4%, now sitting on 525.26m for the twelve trailing months.
volatility
vetoquinol's last week, last month's, and last quarter's current intraday variation average was a negative 1.84%, a negative 0.21%, and a positive 1.39%.
vetoquinol's highest amplitude of average volatility was 2.71% (last week), 1.35% (last month), and 1.39% (last quarter).
more news about vetoquinol.